Cargando…

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

BACKGROUND: While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood. We exami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiniwa, Yukiko, Nakamura, Kenta, Mikoshiba, Asuka, Ashida, Atsuko, Akiyama, Yasuyuki, Morimoto, Atsushi, Okuyama, Ryuhei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968258/ https://www.ncbi.nlm.nih.gov/pubmed/33731038 http://dx.doi.org/10.1186/s12885-021-08016-y

Ejemplares similares

BRAF Mutation Heterogeneity in Melanoma Lesions
por: SAKAIZAWA, Kaori, et al.
Publicado: (2020)

A Case of Apocrine Carcinoma Arising in a Sebaceous Naevus: Detection of HRAS G13R Mutation
por: KATSUIE, Shiho, et al.
Publicado: (2022)

Late Onset of Cardiac Metastasis of a Melanoma following Nivolumab Immunotherapy
por: Nakamura, Kenta, et al.
Publicado: (2022)

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
por: Sakaizawa, K, et al.
Publicado: (2012)

Involvement of local renin‐angiotensin system in immunosuppression of tumor microenvironment
por: Nakamura, Kenta, et al.
Publicado: (2017)

A Two-year-old Boy with a Depressed Area in the Groin: A Quiz
por: OSAWA, Kana, et al.
Publicado: (2022)

Toxic Epidermal Necrolysis Caused by Apalutamide: A Case Report of Treatment Using Etanercept with Conventional Steroid Therapy
por: OSAWA, Kana, et al.
Publicado: (2022)

Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma
por: Nakamura, Kenta, et al.
Publicado: (2022)

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
por: Castellani, Giorgia, et al.
Publicado: (2023)

A nonsense nucleotide substitution in the oculocutaneous albinism II gene underlies the original pink-eyed dilution allele (Oca2(p)) in mice
por: SHOJI, Haruka, et al.
Publicado: (2015)

Erythromelalgia Associated with Neuropathy in Sjögren’s Syndrome: A Case Report
por: SAITO, Nana, et al.
Publicado: (2022)

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
por: Chang-Hao Tsao, Simon, et al.
Publicado: (2015)

Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
por: Suzuki, Rika, et al.
Publicado: (2023)

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
por: Inoue, Hiroyuki, et al.
Publicado: (2016)

Coexpression of EpCAM, CD44 Variant Isoforms and Claudin-7 in Anaplastic Thyroid Carcinoma
por: Okada, Toshihiro, et al.
Publicado: (2014)

Certolizumab pegol treatment for leg ulcers due to rheumatoid vasculitis
por: Meling, Maureen Tania, et al.
Publicado: (2021)

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
por: Gouda, M.A., et al.
Publicado: (2021)

Pink nodule accompanied with clustered yellow globules at the periphery
por: Mikoshiba, Yasutomo, et al.
Publicado: (2017)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
por: Sevilla, Arrate, et al.
Publicado: (2020)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Clinical significance of BRAF mutations in metastatic melanoma
por: Chang, David Z, et al.
Publicado: (2004)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
por: Tatsuno, Michiko, et al.
Publicado: (2016)

Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib
por: Kato, Hiroshi, et al.
Publicado: (2023)

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
por: Schreuer, Max, et al.
Publicado: (2016)

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
por: Salemi, Rossella, et al.
Publicado: (2018)

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
por: Hardeman, Keisha N., et al.
Publicado: (2017)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
por: Edmunds, S C, et al.
Publicado: (2003)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study
por: Forschner, Andrea, et al.
Publicado: (2020)

Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas
por: Lee, Hyoun Wook, et al.
Publicado: (2012)

Current State of Target Treatment in BRAF Mutated Melanoma
por: Tanda, Enrica Teresa, et al.
Publicado: (2020)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pau51hdlbv1qkme7snnl3ecaac